Millennium Earnings No Shocker, But How High Can Velcade Fly?
This article was originally published in The Pink Sheet Daily
Executive Summary
“In flux” myeloma space keeps analysts guessing.
You may also be interested in...
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Japanese drug maker takes a stronger position in oncology, expands U.S. presence.
Takeda Reaffirms Oncology Goals With $8.8 Billion Millennium Acquisition
Japanese drug maker takes a stronger position in oncology, expands U.S. presence.
Celgene: Strong Quarter As Front-Line Myeloma Race Continues
Full-year results up, too, though Millennium’s priority-review Velcade looms.